Drugs / Gammunex-C
Gammunex-C
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03919773 Comparator | Oct 2018 → Jun 2023 | postural orthostatic tachycardia syndrome | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gammunex-C | “Gammunex-C, a form of intravenous immunoglobulin (IVIG), is approved for the treatment of chronic inflammatory demyelinating neuropathy (CIDP) or idiopathic thrombocytopenic...” NCT03919773 ↗ |
| Known as | Gamunex-C | “IVIG (Gamunex-C) Treatment Study for POTS Subjects” NCT03919773 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03919773 ↗ |
| Modality | Protein / enzyme biologic | “Gammunex-C, a form of intravenous immunoglobulin (IVIG)” NCT03919773 ↗ |
| Route | Intravenous | “intravenous immunoglobulin (IVIG)” NCT03919773 ↗ |